Can Pre-Surgery hormone cocktail boost erection recovery in prostate cancer?

NCT ID NCT02949284

Ongoing Disease control Sponsor: Rutgers, The State University of New Jersey Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 11, 2026 · Updated 5 times

Summary

This phase 2 trial tests whether giving hormone therapy before prostate surgery helps men with high-risk prostate cancer recover erectile function better. About 90 men will receive either apalutamide alone or a combination of apalutamide, abiraterone, GnRH agonist, and prednisone before nerve-sparing prostate removal. The goal is to see if these drugs shrink tumors and improve post-surgery potency compared to surgery alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: apalutamide, abiraterone acetate, GnRH agonist, prednisone
What this could lead to: If successful, this approach could help men with high-risk prostate cancer recover erectile function better after surgery, potentially improving quality of life.
What could go wrong: This is a small, early-phase trial (90 participants) testing combinations of drugs before surgery. Results may not apply to all patients, and side effects from hormone therapy can be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH RISK PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STAGE II PROSTATE ADENOCARCINOMA STAGE III PROSTATE ADENOCARCINOMA

Contacts and locations

Locations

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
Yale Cancer Center

New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.